#United States #Aventura #ILUMYA #Sun Pharma #Winlevi

Sun Pharma Presents New Clinical Data at 2026 Winter Clinical Miami

Sun Pharmaceutical Industries Limited (Sun Pharma), a leading global specialty generics company, has unveiled a substantive set of clinical findings during the 2026 Winter Clinical Miami. The event, taking place from February 27 to March 1 in Aventura, Florida, serves as a platform for Sun Pharma to share new data across its dermatology and immunology portfolio, highlighting their commitment to improving patient outcomes.

Expanded Evidence for Key Treatments

Among the 19 abstracts shared at the conference, newly developed findings for ILUMYA® (tildrakizumab-asmn) and WINLEVI® (clascosterone cream 1%) illustrate the company’s innovative spirit. The data reflects real-world usage efficacy, particularly for U.S. patients relying on Medicare, emphasizing patient-centered treatment options.

Dr. Ahmad Naim, Senior Vice President and North American Chief Medical Officer, emphasized the importance of this data by stating, "The findings we presented reflect our commitment to generating robust evidence in the field of dermatology, particularly for conditions such as alopecia areata, plaque psoriasis, and acne. The insights garnered are essential for clinical decision-making among clinicians."

Insights from ILUMYA Studies

The conference features compelling analysis on the use of ILUMYA among patients with moderate-to-severe plaque psoriasis. These findings include:

• - Real-world application of Tildrakizumab in Medicare patients, with a focus on continuity of care.
• - Effectiveness tracking of Tildrakizumab across various geographic regions, showcasing its practical application in diverse clinical settings.

These studies underscore the significant role of ILUMYA in managing complex patient cases and affirm its safety and efficacy.

Advancements with WINLEVI

WINLEVI, which is geared toward acne treatment, showed promising results. Highlights from the data include:

• - A 52-week open-label pilot study that demonstrated sustained improvements in acne severity among patients with skin of color, affirming its safety profile.
• - Combination therapies utilizing WINLEVI yielded additional improvements in patient outcomes, suggesting its versatility in comprehensive acne treatment regimens.

LEQSELVI's Impact on Alopecia Areata

Another key medication highlighted at the Winter Clinical was LEQSELVI™ (deuruxolitinib), focusing on its effects on severe alopecia areata. The findings included:

• - Early indications of scalp hair regrowth in patients treated with LEQSELVI.
• - Data showcased consistent benefits across various patient demographics, including those affected by differing disease durations and involvement of eyebrows and eyelashes.

Patient and Clinician Perspectives

The conference also revealed findings from landmark surveys conducted by Sun Pharma, which aimed to bridge the understanding between clinician and patient priorities in alopecia areata treatment. These surveys shed light on discrepancies in treatment awareness and the prioritization of healthcare goals among patients facing this condition.

Conclusion

As Sun Pharma continues to forge ahead in dermatology and immunology, the data presented at the Winter Clinical Miami enhances the understanding of their treatment methodologies, thereby underscoring the company’s commitment to elevating patient care through evidence-based approaches. With continued innovation, the company seeks to meet the needs of diverse patient populations, further establishing its leadership in the healthcare sector.